Zobrazeno 1 - 10
of 25
pro vyhledávání: ''
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 6, p e0235090 (2020)
PLoS ONE, Vol 15, Iss 6, p e0235090 (2020)
Tumor is a prevalent great threat to public health worldwide and multidrug resistance (MDR) of tumor is a leading cause of chemotherapy failure. Nanomedicine has shown prospects in overcoming the problem. Doxorubicin (DOX), a broad-spectrum anticance
Autor:
Yun Fu, Sheng Guo, Changzheng Li, Tiesuo Zhao, Yun Yang, Yanjie Sun, Yongli Li, Tengfei Huang, Tingting Wang
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 9, p e0215886 (2019)
PLoS ONE, Vol 14, Iss 9, p e0215886 (2019)
The progression of cancer through local expansion and metastasis is well recognized, but preventing these characteristic cancer processes is challenging. To this end, a new strategy is required. In this study, we presented a novel dual functional pod
Autor:
Marta Jezova, Katerina Adamkova, Renata Veselská, Petr Chlapek, Viera Dobrotkova, Jaroslav Sterba, Pavel Mazánek
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 6, p e0218269 (2019)
PLoS ONE, Vol 14, Iss 6, p e0218269 (2019)
Although the administration of retinoids represents an important part of treatment for children suffering from high-risk neuroblastomas, approximately 50% of these patients do not respond to this therapy or develop resistance to retinoids during trea
Autor:
Hon S. Leong, Paul C. Boutros, James C. Lacefield, Matthew R. Lowerison, Alessandro Datti, Joe S. Mymryk, Kara M. Ruicci, John W. Barrett, Stephenie D. Prokopec, Kevin Fung, Karlee Searle, Frederick S. Vizeacoumar, Nicole Pinto, Anthony C. Nichols, Danielle MacNeil, John Yoo
Publikováno v:
PLoS ONE
Anatomy and Cell Biology Publications
PloS one, vol 13, iss 11
PLoS ONE, Vol 13, Iss 11, p e0207152 (2018)
Anatomy and Cell Biology Publications
PloS one, vol 13, iss 11
PLoS ONE, Vol 13, Iss 11, p e0207152 (2018)
Anaplastic thyroid cancer (ATC) is a rare and lethal human malignancy with no known effective therapies in the majority of cases. Despite the use of conventional treatments such as chemotherapy, radiation and surgical resection, this disease remains
Autor:
Joanna Dutko-Gwozdz, Omar N. Pathmanaban, Peter Cueppens, Kenny Yu, Brian A. Telfer, Gareth Griffiths, Ian Peers, Roderick Benson, Kaye J. Williams, Brian W. Bigger, Deniz Beyit, Catherine McBain, Ian Kamaly-Asl, Amir Saam Youshani, Jessica T. Taylor
Publikováno v:
PLoS ONE
Yu, K K H, Taylor, J T, Pathmanaban, O N, Youshani, A S, Beyit, D, Dutko-Gwozdz, J, Benson, R, Griffiths, G, Peers, I, Cueppens, P, Telfer, B A, Williams, K J, McBain, C, Kamaly-Asl, I D & Bigger, B W 2018, ' High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma ', PLoS ONE, vol. 13, no. 3, e0193694 . https://doi.org/10.1371/journal.pone.0193694
PLoS ONE, Vol 13, Iss 3, p e0193694 (2018)
Yu, K K H, Taylor, J T, Pathmanaban, O N, Youshani, A S, Beyit, D, Dutko-Gwozdz, J, Benson, R, Griffiths, G, Peers, I, Cueppens, P, Telfer, B A, Williams, K J, McBain, C, Kamaly-Asl, I D & Bigger, B W 2018, ' High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma ', PLoS ONE, vol. 13, no. 3, e0193694 . https://doi.org/10.1371/journal.pone.0193694
PLoS ONE, Vol 13, Iss 3, p e0193694 (2018)
Background Glioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes remain poor. First line treatment is well established, however disease invariably recurs and improving prognosis is challenging. With the aim o
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 7, p e0180383 (2017)
PLoS ONE, Vol 12, Iss 7, p e0180383 (2017)
Tyrosine kinase inhibitors (TKIs) are currently the first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. These patients receive platinum-based chemotherapy as the second-line tre
Autor:
Gwenda F. Ligon, Theresa LaVallee, Veronique Neumeister, David L. Rimm, Diego Alvarado, Jay S. Lillquist, Gerald McMahon, Scott Seibel, Gerald J. Wallweber
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 7, p e0181356 (2017)
PLoS ONE, Vol 12, Iss 7, p e0181356 (2017)
Head and neck squamous cell carcinoma (HNSCC) accounts for 3-5% of all tumor types and remains an unmet medical need with only two targeted therapies approved to date. ErbB3 (HER3), the kinase-impaired member of the EGFR/ErbB family, has been implica
Autor:
Shuang Wu, Koji Takahashi, Masato Nakamura, Osamu Yokosuka, Reina Sasaki, Shingo Nakamoto, Tatsuo Kanda, Yuki Haga
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 3, p e0174153 (2017)
PLoS ONE, Vol 12, Iss 3, p e0174153 (2017)
Background Despite recent advances in treatment strategies, it is still difficult to cure patients with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase inhibitor for systemic chemotherapy in patients with advanced HCC.
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 1, p e0170415 (2017)
PLoS ONE, Vol 12, Iss 1, p e0170415 (2017)
Head and neck cancer patients suffer from toxicities, morbidities, and mortalities, and these ailments could be minimized through improved therapies. Drug discovery is a long, expensive, and complex process, so optimized assays can improve the succes
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 8, p e0161023 (2016)
PLoS ONE, Vol 11, Iss 8, p e0161023 (2016)
Osteosarcoma is the most common primary bone tumor and poor prognosis for osteosarcoma patients is mainly due to chemotherapy resistance. MicroRNAs are important to maintain pathophysiological mechanisms of cancer and influence cell sensitivity to ch